Epidemiology of Hantavirus infections in humans: a comprehensive, global overview.

Hantaviruses comprise an emerging global threat for public health, affecting about 30,000 humans annually. Infection may lead to Hantavirus pulmonary syndrome (HPS) in the Americas and hemorrhagic fever with renal syndrome (HFRS) in the Europe and Asia. Humans are spillover hosts, acquiring infection primarily through the inhalation of aerosolized excreta from infected rodents and insectivores. Risk factors for infection include involvement in outdoor activities, such as rural- and forest-related activities, peridomestic rodent presence, exposure to potentially infected dust and outdoor military training; prolonged, intimate contact with infected individuals promotes transmission of Andes virus, the only Hantavirus known to be transmitted from human-to-human. The total number of Hantavirus case reports is generally on the rise, as is the number of affected countries. Knowledge of the geographical distribution, regional incidence and associated risk factors of the disease are crucial for clinicians to suspect and diagnose infected individuals early on. Climatic, ecological and environmental changes are related to fluctuations in rodent populations, and subsequently to human epidemics. Thus, prevention may be enhanced by host-reservoir control and human exposure prophylaxis interventions, which likely have led to a dramatic reduction of human cases in China over the past decades; vaccination may also play a role in the future.

Red man syndrome adverse reaction following intravenous infusion of cefepime.

We report the first case of cefepime-induced "red-man syndrome," which appeared 30 min following drug infusion and was confirmed with a rechallenge test. This syndrome is classically associated with vancomycin infusion and is the result of non-IgE mediated mast cell degranulation. While this adverse effect can be easily managed with drug withdrawal and antihistamine administration, it is unknown whether it can be prevented with slower cefepime infusion and preinfusion antihistamines, as is the case with vancomycin.

Hantavirus infections for the clinician: from case presentation to diagnosis and treatment.

Hantaviruses cause Hantavirus Pulmonary Syndrome (HPS; also called Hantavirus Cardiopulmonary Syndrome) in the Americas and Hemorrhagic Fever with Renal Syndrome (HFRS) in Asia and Europe. In Scandinavia and northern Europe, a milder form of HFRS is prevalent, termed nephropathica epidemica (NE). HPS presents with acute respiratory failure, mild-moderate renal failure, thrombocytopenia, and reactive lymphocytosis. HFRS has pronounced renal dysfunction and less prominent respiratory involvement, with thrombocytopenia and hemorrhagic findings. Both syndromes have long-term sequelae. Common symptomatology is due to underlying pathophysiology, mainly increased vascular permeability and immune activation. Laboratory and imaging markers predicting disease severity are under research, allowing for more efficient patient management. Diagnosis is presumptive, based on typical clinical findings and patient history of likely rodent exposure. Confirmation of diagnosis is by serological testing and/or RT-PCR. Treatment is mainly comprised of cardiovascular, respiratory, and renal function support, with fluid and electrolyte homeostasis being crucial components of care. In HPS, the use of extracorporeal membrane oxygenation in decompensated patients has also shown to be beneficial.

Differential diagnosis and treatment of acute cauda equina syndrome in the human immunodeficiency virus positive patient: a case report and review of the literature.

BACKGROUND: Acute cauda equina syndrome is an uncommon but significant neurologic presentation due to a variety of underlying diseases. Anatomical compression of nerve roots, usually by a lumbar disk hernia is a common cause in the general population, while inflammatory, neoplastic, and ischemic causes have also been recognized. Among human immunodeficiency virus (HIV) infected patients with acquired immunodeficiency syndrome, infectious causes are encountered more frequently, the most prevalent of which are: cytomegalovirus, herpes simplex virus 1/2, varicella zoster virus, and Mycobacterium tuberculosis infections. Studies of cauda equina syndrome in well-controlled HIV infection are lacking. We describe such a case of cauda equina syndrome in a well-controlled HIV-infected patient, along with a brief review of the literature regarding the syndrome's diagnosis and treatment in individuals with HIV infection. CASE PRESENTATION: A 36-year-old Greek male, HIV-positive patient presented with perineal and left hemiscrotal numbness, lumbar pain, left-sided sciatica, and urinary incontinence. Magnetic resonance imaging of the patient's lumbar spine revealed intrathecal migration of a fragment from an intervertebral lumbar disk exerting pressure on the cauda equina. A cerebrospinal fluid examination, brain computed tomography scan, spine magnetic resonance imaging, and serological test results were negative for central nervous system infections. Our patient underwent emergency neurosurgical spinal decompression, which resolved most symptoms, except for mild urinary incontinence. CONCLUSIONS: Noninfectious etiologies may also cause cauda equina syndrome in HIV-infected individuals, especially in well-controlled disease under antiretroviral therapy. Prompt recognition and treatment of the underlying cause is important to minimize residual symptoms. Targeted antimicrobial chemotherapy is used to treat infectious causes, while prompt surgical decompression is favored for anatomical causes of cauda equina syndrome in the HIV-infected patient.

Epidemiological and behavioral factors associated with Crimean-Congo hemorrhagic fever virus infections in humans.

Crimean-Congo hemorrhagic fever (CCHF), a viral disease with high fatality rate, is endemic in many countries in Europe, the Middle East, Asia and Africa. It is transmitted to humans either by tick bite or by direct contact with blood or tissues of viremic patients or livestock. Aim of the present study was to review the main epidemiological characteristics of the disease worldwide, with special attempt to show the epidemiological and behavioral factors that play a role in acquisition of the infection. It is obvious that these factors differ among countries, and the knowledge and understanding of the transmission routes in each region facilitates the implementation of proper control measures, the awareness enhancement and the prevention of the disease.

Crimean-Congo hemorrhagic fever: seroprevalence and risk factors among humans in Achaia, western Greece.

BACKGROUND: The Crimean-Congo hemorrhagic fever virus (CCHFV) presents a wide distribution, with the Balkan Peninsula being among the endemic regions. To date, only one CCHF case has been reported in Greece; however, based on seroprevalence data, there is evidence that CCHFV circulates in the country. Achaia is a prefecture in western Greece that has not previously been studied for CCHFV. OBJECTIVES: The aim of this study was to estimate the seroprevalence of CCHFV in humans in Achaia Prefecture, Greece, and to assess possible factors playing a role in seropositivity. METHODS: A total of 207 serum samples from people of all age groups, from both urban and rural areas, were prospectively collected and tested for IgG antibodies against CCHFV. RESULTS: The overall seroprevalence was 3.4%, with significant differences among municipalities. An agro-pastoral occupation, contact with sheep and goats, former tick bite, increasing age, and living at an altitude of ≥400 m, on specific land cover types, were significantly associated with CCHFV seropositivity. CONCLUSIONS: A relatively high seroprevalence was detected in a previously unstudied region of Greece, where CCHFV infection seems to occur mainly through tick bites. Further investigations are needed to identify the circulating CCHFV strains in Greece, in order to gain a better understanding of CCHFV ecology and epidemiology in the country.

Beta2-adrenergic activation via administration of atenolol/formoterol combination increases contractility and coronary blood flow in isolated rat hearts.

INTRODUCTION: Commonly used adrenergic agonists in low cardiac output scenarios rely primarily on beta1adrenergic activation to stimulate cardiac function. Little is known about the use of beta2-adrenergic agonist administration for this purpose, although the associated vasodilation may be beneficial. This study was conducted in order to assess the efficacy of one such beta2-adrenergic agonist, formoterol, in augmenting cardiac function. METHODS: The hearts of 8 anesthetized female Wistar rats were excised, and subsequently kept functional in an isolated heart preparation (Langendorff apparatus). After placement on the apparatus, hearts were subjected to the beta1-blocker, atenolol, and then to a combination of formoterol/atenolol. Left ventricular developed pressure (LVDP), heart rate (HR), and coronary flow (CF) were monitored. RESULTS: CF showed a median increase of 16% (p<0.05) after formoterol/atenolol administration, with this effect lasting 20 min post-administration. Furthermore, statistically significant differences included an early 26% increase in LVDP and a late 21% increase in HR. The CF increase was independent of HR and LVDP changes. CONCLUSIONS: Our results indicate that the beta2-agonist formoterol not only successfully increases heart rate and contractility, but also increases coronary flow, most likely by means of beta2-mediated coronary vasodilation. This pharmacological profile may prove to be especially beneficial in situations where cardiac output must be increased, while adequate myocardial oxygen delivery needs to be maintained.